Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| Panitumumab with capecitabine and oxaliplatin (CAPOX) followed byNCT00346099 | NSABP Foundation IncPHASE2 | WITHDRAWN Protocol closed based on new (and as yet unpublished) information from a phase II clinical trial. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2008-01-07 |
| Lactobacillus GGNCT00220519 | Shriners Hospitals for ChildrenNA | TERMINATED Study stopped due to low enrollment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-01-07 |
| Staph aureus types 5 and 8 conjugate vaccineNCT00130260 | Nabi BiopharmaceuticalsPHASE3 | TERMINATED unsatisfactory efficacy data from preceding trial | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-01-04 |
| Onco-peptide loaded autologous dendritic cellsNCT00197925 | Herlev HospitalPHASE1, PHASE2 | TERMINATED all patients recruited | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-01-03 |
| hCRFNCT00226668 | Celtic Pharma Development ServicesPHASE3 | WITHDRAWN Alternate study projected to assess imaging endpoints versus clinical endpoints. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-01-03 |
| Gleevec, TaxotereNCT00209079 | Emory UniversityPHASE2 | TERMINATED Terminated 4/17/07. Drug sponsor withdrew. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-31 |
| MitoxantroneNCT00146159 | Wyeth is now a wholly owned subsidiary of PfizerPHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-12-28 |
| doxorubicinNCT00165087 | Dana-Farber Cancer InstitutePHASE3 | TERMINATED Terminated by IRB for continuing review | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-12-28 |
| dexrazoxaneNCT00165087 | Dana-Farber Cancer InstitutePHASE3 | TERMINATED Terminated by IRB for continuing review | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-12-28 |
| asparaginase (Erwina)NCT00165087 | Dana-Farber Cancer InstitutePHASE3 | TERMINATED Terminated by IRB for continuing review | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-12-28 |
| asparaginase (E. Coli)NCT00165087 | Dana-Farber Cancer InstitutePHASE3 | TERMINATED Terminated by IRB for continuing review | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-12-28 |
| PLA-695NCT00396955 | Wyeth is now a wholly owned subsidiary of PfizerPHASE2 | TERMINATED imbalance of gastrointestinal and the lipase events | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2007-12-28 |
| BL22 immunotoxinNCT00077493 | MedImmune LLCPHASE1 | SUSPENDED protocol development and Amended protocol revision | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-28 |
| rhEndostatinNCT00165373 | Dana-Farber Cancer InstitutePHASE1 | TERMINATED Lack of drug supply | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-28 |
| Combination of Temsirolimus and SunitinibNCT00417677 | Wyeth is now a wholly owned subsidiary of PfizerPHASE1, PHASE2 | TERMINATED Decision was made not to attempt a lower dose | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-28 |
| ThymoglobulinNCT00040651 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)PHASE1 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-28 |
| CyclophosphamideNCT00040651 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)PHASE1 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-28 |
| FludarabineNCT00040651 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)PHASE1 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-28 |
| PPM-204NCT00425919 | Wyeth is now a wholly owned subsidiary of PfizerPHASE2 | TERMINATED Study terminated as a result of interim analysis not meeting predetermined criteria. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-12-27 |
| Pindolol and venlafaxinNCT00159146 | Hillerod Hospital, DenmarkNA | TERMINATED lack of participants fulfilling inclusion criteria | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-27 |
| LubriDermNCT00492479 | Innovative MedicalPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2007-12-24 |
| Kinerase Pro+Therapy Line Ultra rich day repairNCT00492479 | Innovative MedicalPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2007-12-24 |
| Kinerase Pro+Therapy Line day repair, serum, night repairNCT00492479 | Innovative MedicalPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2007-12-24 |
| epoetin beta [NeoRecormon]NCT00440063 | Hoffmann-La RochePHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2007-12-20 |
| Folic acidNCT00570856 | Shahid Beheshti University of Medical SciencesPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-19 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |